Kun Run Biotech (PINK:KURU)

Kun Run Biotech came public via a reverse merger on September 16, 2008

Kun Run Biotechnology, Inc., together with its subsidiaries, engages in manufacture and sale of polypeptide medicines. It uses solid phase peptide synthesis (SPPS) and advanced purifying technology to produce various therapeutic polypeptide drugs, of which is 'TP-5' most known for efficiently regulating humans' immune systems in order to defend and cure malignant diseases. The company maintains two state-of-art manufacturing plants and possesses one of the largest peptide synthesizing capacities across Asia.

Web site: http://www.zhonghe.cn

Last updated April 1, 2009